$GILD (Gilead Sciences Inc.)

$GILD {{ '2016-04-28T21:01:44+0000' | timeago}} • Webcast

Foster City, California-based biotechnology company $GILD said that with the approval of its three new regimens, the company is able to offer a range of options to address the diverse medical requirements of people with HIV. TAF was added to the medicines patent pool and into various access programs.

$GILD {{ '2017-10-27T18:39:37+0000' | timeago}} • Webcast

$GILD expects Yescarta will become the standard-of-care for diffuse large B-cell lymphoma after oral therapy. The company has done the clinical trials in diffuse large B-cell lymphoma in around 15 centers mainly focusing in the US. $GILD is currently expanding to most centers in the US and also in Europe.

$GILD {{ '2017-10-27T18:39:19+0000' | timeago}} • Webcast

In 3Q17, $GILD’s HIV and HBV franchise delivered revenues of $2.7Bil in the US. TAF-based regimens now account for 56% of the company’s total HIV prescription volume, up from 39% as it entered 2017. In Europe, total HIV and HBV revenues were $716MM in 3Q17, down 2% YoY and down 2% sequentially.

$GILD {{ '2017-10-27T18:39:01+0000' | timeago}} • Webcast

During 3Q17, $GILD’s product sales in the US were $4.5Bil, down 10% YoY and 9% sequentially. HCV product sales were $1.4Bil, down 31% YoY and 26% sequentially, primarily driven by lower patient starts and increased competition. Non-HCV product sales were $3.1Bil, up 4% YoY, and 2% sequentially, primarily due to higher demand for TAF-based regimens.

$GILD {{ '2017-10-26T23:24:11+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 4Q17, payable on December 28, 2017, to stockholders of record on December 15, 2017.

$GILD {{ '2017-10-26T23:20:36+0000' | timeago}} • Announcement

For FY17, $GILD expects net product sales to be $24.5-25.5Bil. Non-HCV product sales are expected to be $16-16.5Bil while HCV product sales are expected to be $8.5-9Bil. Adjusted product GM is expected to be 86-87%.

$GILD {{ '2017-10-26T23:20:20+0000' | timeago}} • Announcement

$GILD reported net income of $2.7Bil or $2.06 per share in 3Q17 compared to $3.3Bil or $2.49 per share in 3Q16. Adjusted net income was $3Bil or $2.27 per share in 3Q17. Total revenues were $6.5Bil in 3Q17 compared to $7.5Bil in 3Q16.

$GILD {{ '2017-10-26T21:11:34+0000' | timeago}} • Infographic

$GILD Gilead Sciences Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$GILD {{ '2017-10-24T15:21:32+0000' | timeago}} • Announcement

$GILD announced positive results from a Phase 2 trial evaluating GS-0976 in the treatment of nonalcoholic steatohepatitis (NASH). After 12 weeks, a higher dose of GS-0976 was associated with significant reductions in liver fat buildup and a noninvasive marker of fibrosis compared to placebo. NASH is a disease that can significantly harm the liver.

$GILD {{ '2017-10-19T16:10:20+0000' | timeago}} • Announcement

$GILD received approval from the US FDA for Yescarta, a new gene therapy developed by Kite Pharma for the treatment of adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Yescarta is a CAR-T therapy, which reprograms the body’s own immune cells to recognize and attack malignant cells.

$GILD {{ '2017-10-17T16:06:03+0000' | timeago}} • Announcement

$GILD announced the promotion of Alessandro Riva, MD, to EVP, Oncology Therapeutics, with responsibility for the company’s hematology and oncology programs, including cell therapy research and development.

$GILD {{ '2017-10-04T14:22:07+0000' | timeago}} • Announcement

$GILD announced results from a Phase 3 study evaluating the efficacy of a fixed-dose combination of bictegravir (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (FTC/TAF), a dual-NRTI backbone in HIV-1-infected patients. The study found BIC/FTC/TAF to be superior to other regimens.

$GILD {{ '2017-10-04T13:59:54+0000' | timeago}} • Announcement

$GILD has also expanded its licensing agreements with Sun Pharmaceutical Industries Limited, Strides Shasun Limited, Mylan Laboratories Limited and SeQuent Scientific Limited to include BIC, and products incorporating the compound, for distribution in 116 developing countries.

$GILD {{ '2017-10-04T13:59:38+0000' | timeago}} • Announcement

$GILD announced a new licensing agreement with the Medicines Patent Pool (MPP) to expand access to bictegravir (BIC) upon regulatory approval in the US. BIC is used to treat HIV-1 infection. MPP can sub-license rights to BIC to companies in India, China and South Africa to manufacture therapies containing BIC for distribution in 116 countries.

$GILD {{ '2017-09-27T21:15:40+0000' | timeago}} • Announcement

$GILD announced that Kevin Young CBE, COO, plans to retire, effective early 2018. Mr. Young will remain with $GILD through 1Q18 and in an advisory capacity thereafter.

$GILD {{ '2017-09-26T13:43:32+0000' | timeago}} • Announcement

$GILD and $KITE announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to $GILD’s cash tender offer for $KITE expired on September 25, 2017. With the expiration of the waiting period, the tender offer is expected to close in the beginning of October 2017, subject to closing conditions.

$GILD {{ '2017-09-25T12:54:53+0000' | timeago}} • Announcement

$GILD said that the China Food and Drug Administration has approved Sovaldi,  a once-daily oral inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi is the first Gilead HCV medicine approved in China. Sovaldi received marketing approval from the US FDA in 2013 and the European Commission in 2014.

$GILD {{ '2017-09-15T13:21:02+0000' | timeago}} • Announcement

$GILD announced the pricing of senior unsecured notes in an aggregate principal amount of $3Bil, in an underwritten, registered public offering. The offering is expected to close September 21, 2017, subject to customary closing conditions. $GILD intends to use the net proceeds from the offering to finance a portion of the Kite acquisition.

$GILD {{ '2017-08-28T14:12:29+0000' | timeago}} • Announcement

$GILD agreed to acquire $KITE for $180 per share in cash, or approx. $11.9Bil in total. The deal is expected to close in 4Q17, and is expected to be neutral to earnings by year three and accretive thereafter. $GILD plans to finance the transaction with a combination of cash on hand, bank debt and senior unsecured notes.

$GILD {{ '2017-08-02T13:17:21+0000' | timeago}} • Announcement

$GILD announced that the US FDA has approved updated labeling for Epclusa, an all-oral, pan-genotypic, once-daily single tablet regimen for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.

$GILD {{ '2017-07-27T19:17:21+0000' | timeago}} • Webcast

$GILD stated that for Genvoya, it is starting to see performance trends similar to that of the US in other countries like Germany. The company is seeing good uptake in Spain and Italy. France has also done extraordinarily well in just four months to become the leading naïve and switch product.

Recent Transcripts

PDCO (Patterson Companies, Inc.)
Tuesday, November 21 2017 - 3:00pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
CEMI (Chembio Diagnostics, Inc.)
Wednesday, November 8 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
NVAX (Novavax, Inc.)
Tuesday, November 7 2017 - 9:30pm
PTX (Pernix Therapeutics Holdings, Inc.)
Tuesday, November 7 2017 - 9:30pm
PDLI (PDL BioPharma, Inc.)
Thursday, November 2 2017 - 8:30pm
NSTG (NanoString Technologies, Inc.)
Thursday, November 2 2017 - 8:30pm
INSM (Insmed Incorporated)
Thursday, November 2 2017 - 12:30pm
NBIX (Neurocrine Biosciences Inc.)
Wednesday, November 1 2017 - 9:00pm
MNTA (Momenta Pharmaceuticals Inc.)
Wednesday, November 1 2017 - 2:00pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm
UTHR (United Therapeutics Corporation)
Wednesday, October 25 2017 - 1:00pm
ILMN (Illumina Inc.)
Tuesday, October 24 2017 - 9:00pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm
PETS (PetMed Express, Inc.)
Monday, October 23 2017 - 12:30pm

AlphaGraphics you may like